ULURU Inc. Business Update And Outlook
ADDISON, Texas, March 18, 2013 /PRNewswire/ -- ULURU Inc.
(OTCQB: ULUR) today provided a business update and outlook for
the balance of 2013.
The current focus of our business activities is on the expansion
of our global commercialization of Altrazeal® in
conjunction with Altrazeal Trading Ltd. Currently, Altrazeal
Trading Ltd. is in the process of establishing a global network of
sales and marketing partners with the necessary capabilities to
maximize the market potential of Altrazeal®.
Based on the success achieved to-date establishing marketing
partnerships, it is anticipated that by the end of the second
quarter of 2013 initial product shipments will have been made to
5-6 international sales partners.
Commenting on the international commercialization of
Altrazeal®, Helmut
Kerschbaumer, Managing Director of Altrazeal Trading Ltd.,
stated, "With the extensive clinical experience in Europe and Australia, supported by the data previously
generated in the United States we
have developed significant interest from potential sales and
marketing partners in many European markets, including Eastern Europe, Turkey, the Middle
East, the Indian subcontinent and South Africa. We are now in the very favorable
position of having the opportunity to evaluate multiple potential
sales and marketing partners in markets to ensure that these
companies have the required capabilities to effectively sell and
market Altrazeal® and maximize its long-term market
potential. We have now completed agreements for two territories in
the EU with product launches projected for summer 2013.
Furthermore, we anticipate conclusion of additional agreements for
4 – 5 more territories within the next 60 – 90 days. We couldn't be
more pleased with the response that we are receiving from potential
marketing partners throughout the territory."
It is the Company's objective to have Altrazeal®
marketed in over 15 markets by year-end 2013. Based on achieving
this objective, the Company anticipates that it will generate both
positive cash flow and be earnings before interest, taxes,
depreciation and amortization (EBITDA) positive for the fourth
quarter 2013. Also, given the successful roll-out of
Altrazeal®, the Company believes it will not be
necessary to raise additional capital beyond the capital that has
been already committed to the Company.
Commenting on the business update and outlook, Kerry P. Gray, President and CEO of ULURU
stated, "It is gratifying to see that the clinical and economic
benefits of Altrazeal® are being recognized and that
Altrazeal® will have been launched in many important
international markets by year-end 2013. It will indeed be an
important and significant milestone when the Company generates
positive cash flow. This will establish the foundation for exciting
growth in 2014 and beyond. The pieces are now being put in place to
maximize the long term revenue potential of
Altrazeal®."
The Company has recently initiated the production process for
the manufacturing of a 2 gram blister pack, initially for
introduction onto the international markets and subsequently for
the United States market. Based on
the overwhelming positive response to the 0.75 gram blister pack, a
2 gram blister pack configuration has been developed to replace the
2 gram aluminium pouch presentation. It is anticipated that the
initial international shipment of the 2 gram blister pack will be
made in June 2013.
About Altrazeal®:
Altrazeal® is an advanced scientifically
engineered material that is unique in the field of advanced wound
care dressings in terms of properties and performance. It
incorporates the features and benefits of the desired "ideal" wound
dressing. Altrazeal® has demonstrated potential clinical
and economic advantages in a number of chronic and acute wounds
including diabetic foot ulcers, venous leg ulcers, pressure ulcers
and geriatric wounds.
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company
focused on the development of a portfolio of wound management and
oral care products to provide patients and consumers improved
clinical outcomes through controlled delivery utilizing its
innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal
delivery system. For further information about ULURU Inc.,
please visit our website at www.ULURUInc.com. For further
information about Altrazeal®, please visit
www.Altrazeal.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended, including but not limited to statements
made relating to the interest of and the success establishing
marketing partners, initial shipments to international sales
partners, the extensive clinical experience in Europe, Australia and the
United States, potential for the conclusion of additional
marketing agreements, objective to have
Altrazeal® markets by year-end 2013 in 15
markets, generation of positive cash flow and EBITDA in the fourth
quarter of 2013, need for additional capital and the clinical and
economic benefits of Altrazeal®. These statements
are subject to numerous risks and uncertainties, including but not
limited to ULURU's lack of profitability, the need for additional
capital to operate its business, and to risk factors detailed in
the Company's Annual Report on Form 10-K for the year ended
December 31, 2011, and other reports
filed by us with the Securities and Exchange
Commission.
Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
SOURCE ULURU Inc.